Galectin Therapeutics (GALT) Doses First Patients with Fatty Liver Disease
Galectin Therapeutics (NASDAQ:GALT - News), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has been making impressive strides in the development of its GR-MD-02 treatment for patients with fatty liver disease with advanced fibrosis. After submitting a Fast Track application to the FDA earlier this month, the company today announced that its first patient was dosed in GR-MD-02’s Phase I clinical trial.
With no treatments for fatty liver disease with advanced fibrosis currently available, the company’s GR-MD-02 represents a potential first-in-class treatment to the nine million to 15 million Americans, including children, which are affected by the silent epidemic. The only alternative for these patients is a transplant, but there are limited donors available and the procedure is very costly, making this treatment extremely valuable to both the company and its potential patients.
The Phase I multi-center, partially-blinded clinical trial will be conducted in 24 patients with fatty liver disease and advanced fibrosis, who will receive four weekly doses of GR-MD-02 at one of six U.S. centers with extensive experience treating the disease. While early data from the clinical trial will primarily be safety-based, investors are hoping that signs of efficacy will also be observed in the small patient cohort, making it an event certainly worth watching closely.
Investors in fibrosis-focused stocks like Vertex Pharmaceuticals Inc. (NASDAQ:VRTX - News) or cancer-related stocks like Exelixis Inc. (NASDAQ:EXEL - News) may want to take a closer look at the stock as it progresses through these clinical trials, particularly as it may be approved for fast-track status.
About Emerging Growth LLC
EGC is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx